FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:1758 April 17, 2008 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Curfman, G. D. PubMed Citation

To the Editor: Three cheers for the Journal for recognizing the importance of the Supreme Court's upcoming rulings on "FDA [Food and Drug Administration] preemption" cases: whether the fact that a drug or medical device is in compliance with FDA regulations ought to shield its manufacturer from product-liability claims. In your editorial on this topic (Jan. 3 issue),¹ you rightfully describe these cases as having "major, even momentous, implications" for patients' rights and manufacturers' accountability.

There is one point in the editorial that needs clarification. Warner-Lambert v. Kent — which concerns drugs rather than devices — turns on a Michigan . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.